Drug Approval | October 06, 2025
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Investment to expand manufacturing and global medicine supply capacity
The new site enables end-to-end production of viral vector gene therapies
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
The lab will facilitate the development of herbal and natural-based solutions
The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital,
Prior to this appointment, he served as Vice-Chancellor of Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur,
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
Subscribe To Our Newsletter & Stay Updated
